CLINICAL AND DIAGNOSTIC FEATURES OF ENDOMETRIAL HYPERPLASTIC PROCESSES IN POSTMENOPAUSAL WOMEN

Authors:

Abstract:

The study included data from 65 patients with endometrial hyperplasia in the postmenopausal period, of which 56 (86.2 %) had spotting, 32 (49.2 %) had sleep disorders, 29 (44.6 %) had emotional lability, 21 (32.3 %) had dysuric phenomena, 20 (30.8 %) had pain of varying intensity, 15 (23.1 %) had rapid fatigue, and 7 (10.0 %) had bleeding. Studies have found that 85.5 % of women had a history of high birth rates, of which 100 % of women had artificial abortions. The frequency of infertility in this group of patients was 5.2 %. 12 (18.5 %) patients had episodes of recurrent endometrial hyperplasia in the reproductive period. The data of the transvaginal echography showed that the most specific echographic indicator in postmenopausal endometrial hyperplasia is an increase in the thickness of the endometrium, ranging from 14.1±1.6 mm in patients with atypical endometrial hyperplasia to 21.3±4.8 in patients with diffuse endometrial hyperplasia. The study of the parameters of CA 125 revealed its significant fluctuations, which proved the lack of diagnostic significance in this pathology.

Keywords:

postmenopausal period endometrial pathology endometrial polyp atypical endometrial hyperplasia body mass index infertility transvaginal echography

References:

1. Amiraslanov AT, Safarova SI. Faktory riska i prognosticheskie pokazateli atipicheskoy giperplazii endometriya. Vestnik sovremennoy klinicheskoy meditsiny, 2019;12 (2) :7–11. https://doi.org/10.20969/VSKM.2019.12(2).7–11 [in Russian]
2. Gabidullina RI, Smirnova GA, Nuhbala FR. Giperplasticheskie protsessy endometriya: sovremennaya taktika vedeniya patsientok. Consilium Medicum. Moskva 2019; 21 (6): 53–58 https://doi.org/10.26442/20795696.2019.6.190472 [in Russian]
3. Kuznetsova IV, Mychka VB, Kirillova MJu. Sovremennaya kombinirovannaya gormonalnaya terapiya u zhenshhin v ranney postmenopauze. Kardiovaskulyarnaya terapiya i profilaktika 2012; 11(4):42–51. https://doi/org/10.15829/1728–8800–2012–4–42–51 [in Russian]
4. Pushkarev VA, Mustafina GT, Husnutdinov ShM. Zhelezistaya giperplaziya endometriya. Diagnostika, klinika, lechenie. Kreativnaya khirurgiya i onkologiya. 2013; (4):23–7 [in Russian]
5. Rymashevskiy AN, Vorobyev SV, Andryushhenko JuA. Osobennosti razvitiya polipov endometriya u bolnykh s ozhireniem v postmenopauze. Vestnik novykh meditsinskikh tekhnologiy, 2011; XVIII (4): 109–111. [in Russian]
6. Chestnova GP, Kuljushina EA, Abashin VG, Efimenko NA. Osobennosti diagnostiki giperplasticheskikh protsessov v endometrii u zhenshhin v period dlitelnoy postmenopauzy. Klinicheskaya Meditsina, 2013; 9: 46–47. [in Russian]
7. Aune D, Navarro Rosenblatt D.A. Antropometric factors and endometrial cancer risk: A systematic rewiew and meta–analysis of prospective studies. Ann.Oncol., 2015; 26 (8):1635–1648.
8. Brinton L, Felix A. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomarkers Prev. 2018; 27(9): 985–994. https://doi.org/10.1158/1055–9965. EPI–18–0264.
9. Crosbie E, Roberts C, Qian W, Swart A, Kitchener H. Body mass index does not influence post–treatment survival in early stage endometrial cancer: results from eh MRC ASTEC trial. Eur.J.Cancer., 2012; 48: 853–864.
10. Ghoubara A, Emovon E, Sundar S, Ewies A. Thickened endometrium in asymptomatic postmenopausal women – determining an optimum threshold for prediction of atypical hyperplasia and cancer. J Obstet Gynaecol. 2018; 38 (8): 1146–9.
11. Pennant ME, Mehta R, Moody P, Hackett G, Prentice A. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017; 124(3):404–11. https://doi.org/:10.1111/1471–0528.14385
12. Van Hanegem N, Breijer MC, Khan KS. Diagnostic evaluation of the endometrium in postmenopausal bleeding: An evidence–based approach. Maturitas. 2011;68(2):155–64. https://doi.org/:10.1016/j.maturitas.2010.11.010.
13. Wang Y, Nisenblat V, Tao L. Combined estrogen–progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three–year single center experience. J Gynecol Oncol 2019 30(3): e49 https://doi.org/10.3802/jgo.2019.30.e49
14. Werner HMJ, Berg, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low–grade endometrioid carcinomas. Mod Pathol 2012; 26:428–434
15. Wise M.R, Jordan V, Lagaset A. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am.J.Obstet.Gynecol. 2016; .214(6): 689 https://doi.org/10.1016/j.ajog.2016.01.175.

Publication:

«World of Medicine and Biology» Vol. 17 No. 76 (2021) , с. 23-28
УДК 618.145–007.61–07

DOI:

https://doi.org/10.26724/2079-8334-2021-2-76-23-28